Evaluation of the efficacy of bromfenac sodium in the treatment of dry eye disease
DOI: 10.32364/2311-7729-2024-24-1-2
I.A. Loskutov, E.F. Semashko, E.N. Khomyakova, E.I. Makukha, N.E. Kostina
M.F. Vladimirskiy Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
Background: to date, the efficacy of anti-inflammatory treatment in dry eye disease (DED) is still relevant.
Aim: to evaluate the efficacy and safety of bromfenac sodium 0.09% ophthalmic solution plus artificial tears in patients with DED.
Patients and Methods: 175 patients (350 eyes) with DED receiving artificial tears were enrolled. Subjective and objective assessment of symptom severity was performed and DED stage was determined before and 4 weeks after treatment with bromfenac sodium 0.09% ophthalmic solution based on the results of the Ocular Surface Disease Index (OSDI) questionnaire, Schirmer's test and Norn's test. Adverse events were registered to assess the safety of bromfenac sodium 0.09%.
Results: complex treatment of DED resulted in a 1.4-fold increase in Schirmer's test and Norn's test score and a significant improvement in typical symptoms based on the OSDI score. The average OSDI score decreased by 56% compared to baseline. The number of patients with moderate to severe DED decreased by 7% and 55% respectively. The number of patients with mild DED increased by 21%. After 4 weeks of treatment, 41% of patients were symptom free. All changes during the study were significant (p<0.05). No adverse events were reported with the use of bromfenac sodium 0.09%.
Conclusion: bromfenac sodium 0.09% ophthalmic solution is clinically effective in DED. This medication increases total tear production, reduces the severity of symptoms and decreases the number of patients with severe and moderate disease, thereby improving the quality of life of these patients.
Keywords: bromfenac sodium, OSDI, dry eye disease, Schirmer's test, treatment efficacy.
For citation: Loskutov I.A., Semashko E.F., Khomyakova E.N., Makukha E.I., Kostina N.E. Evaluation of the efficacy of bromfenac sodium in the treatment of dry eye disease. Russian Journal of Clinical Ophthalmology. 2024;24(1):7–13 (in Russ.). DOI: 10.32364/2311-7729-2024-24-1-2.
Igor A. Loskutov — Dr. Sc. (Med.), Professor, Head of the Ophthalmological Department, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0000-0003-0057-3338.
Ekaterina F. Semashko — resident of the 2nd year of the Department of Ophthalmology and Optometry, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0009-0004-7993-2667.
Elena N. Khomyakova — C. Sc. (Med.), associate professor of the Department of Ophthalmology and Optometry, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0000-0002-4460-3968.
Elena I. Makukha — ophthalmologist, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0009-0001-3211-9888.
Nataliya E. Kostina — ophthalmologist, assistant of the Department of General Medical Practice (Family Medicine) with the Course of Geriatrics, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0009-0004-1262-1186. Contact information: Ekaterina F. Semashko, e-mail: katuche98@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 01.12.2023.
Revised 22.12.2023.
Accepted 19.01.2024.
2. Сахнов С.Н., Янченко С.В., Малышев А.В. и др. Эпидемиология синдрома «сухого глаза» у пациентов перед рефракционными операциями. Офтальмология. 2018;15(1):92–101. DOI: 10.18008/1816-5095-2018-1-92-101. [Sakhnov S.N., Yanchenko S.V., Malyshev A.V. et al. Dry Eye Epidemiology in Patients before Refractive Operations. Ophthalmology in Russia. 2018;15(1):92–101 (in Russ.)]. DOI: 10.18008/1816-5095-2018-1-92-101.
3. Stapleton F., Alves M., Bunya V.Y. et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–365. DOI: 10.1016/j.jtos.2017.05.003.
4. Marshall L.L., Roach J.M. Treatment of Dry Eye Disease. Consult Pharm. 2016;31(2):96–106. DOI: 10.4140/TCP.n.2016.96.
5. Willcox M.D.P., Argüeso P., Georgiev G.A. et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017;15(3):366–403. DOI: 10.1016/j.jtos.2017.03.006.
6. Ganesalingam K., Ismail S., Sherwin T., Craig J.P. Molecular evidence for the role of inflammation in dry eye disease. Clin Exp Optom. 2019;102(5):446–454. DOI: 10.1111/cxo.12849.
7. Pflugfelder S.C. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337–42. DOI: 10.1016/j.ajo.2003.10.036.
8. Fujishima H., Fuseya M., Ogata M., Murat D. Efficacy of bromfenac sodium ophthalmic solution for treatment of dry eye disease. Asia Pac J Ophthalmol (Phila). 2015;4(1):9–13. DOI: 10.1097/APO.0000000000000032.
9. Максимов М.Л., Звегинцева А.А., Каннер И.Д., Лапкин Н.М. Возможности применения бромфенака в офтальмологической практике. Клиническая офтальмология. 2021;21(4):241–248. DOI: 10.32364/2311-7729-2021-21-4-241-248. [Maksimov M.L., Zvegintseva A.A., Kanner I.D., Lapkin N.M. Bromfenac in ophthalmic practice. Russian Journal of Clinical Ophthalmology. 2021;21(4):241–248 (in Russ.)]. DOI: 10.32364/2311-7729-2021-21-4-241-248.
10. Hoffman R.S., Braga-Mele R., Donaldson K. et al. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2016;42(9):1368–1379. DOI: 10.1016/j.jcrs.2016.06.006.
11. Морозова Т.А. К вопросу оптимального выбора нестероидных противовоспалительных средств в схеме ведения пациента с катарактой. Клиническая офтальмология. 2023;23(1):54–59. DOI: 10.32364/2311-7729-2023-23-1-54-59. [Morozova T.A. On the optimal selection of nonsteroidal anti-inflammatory drugs in the management scheme of cataract patients. Russian Journal of Clinical Ophthalmology. 2023;23(1):54–59 (in Russ.)]. DOI: 10.32364/2311-7729-2023-23-1-54-59.
12. Waterbury L.D., Silliman D., Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22(6):1133–1140. DOI: 10.1185/030079906X112471.
13. Baklayan G.A., Patterson H.M., Song C.K. et al. 24-hour evaluation of the ocular distribution of (14) C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008;24(4):392–398. DOI: 10.1089/jop.2007.0082.
14. Donnenfeld E.D., Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin. 2006;46(4):21–40. DOI: 10.1097/01.iio.0000212134.83513.11.
15. El-Shazly A.H., El-Gohary A.A., El-Shazly L.H., El-Hossary G.G. Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits. Acta Pharm. 2008;58(2):163–173. DOI: 10.2478/v10007-008-0009-0.
16. Jones J., Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother. 2009;10(14):2379–2385. DOI: 10.1517/14656560903188425.
17. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217(2):89–98. DOI: 10.1159/000068563.
18. Si E.C., Bowman L.M., Hosseini K. Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. J Ocul Pharmacol Ther. 2011;27(1):61–66. DOI: 10.1089/jop.2010.0103.
19. Silverstein S.M., Jackson M.A., Goldberg D.F., Muñoz M. The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery. Clin Ophthalmol. 2014;8:965–972. DOI: 10.2147/OPTH.S60292.
20. Henderson B.A., Gayton J.L., Chandler S.P. et al. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology. 2011;118(11):2120–2127. DOI: 10.1016/j.ophtha.2011.04.035.
21. McGhee C.N., Dean S., Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33–55. DOI: 10.2165/00002018-200225010-00004.
22. Naoko K., Hidemi S., Masahiko F. Post-Marketing Surveillance of Bromfenac Sodium (BRONUCK) Ophthalmic Solution-Use-Results Surveillance. Atarashii Ganka. 2005;22:1299–1308.
23. Hoy S.M. Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease. Drugs. 2017;77(17):1909–1916. DOI: 10.1007/s40265-017-0834-x.
24. Toker E., Asfuroğlu E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea. 2010;29(2):133–140. DOI: 10.1097/ICO.0b013e3181acf68d.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
